These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8597035)

  • 1. 1995 Deichmann Lecture--p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment.
    Harris CC
    Toxicol Lett; 1995 Dec; 82-83():1-7. PubMed ID: 8597035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutations in human cancers.
    Hollstein M; Sidransky D; Vogelstein B; Harris CC
    Science; 1991 Jul; 253(5015):49-53. PubMed ID: 1905840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment.
    Harris CC
    Environ Health Perspect; 1996 May; 104 Suppl 3(Suppl 3):435-9. PubMed ID: 8781359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer.
    Hussain SP; Harris CC
    Mutat Res; 1999 Jul; 428(1-2):23-32. PubMed ID: 10517975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment.
    Hussain SP; Hofseth LJ; Harris CC
    Lung Cancer; 2001 Dec; 34 Suppl 2():S7-15. PubMed ID: 11720736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung.
    Hussain SP; Amstad P; Raja K; Sawyer M; Hofseth L; Shields PG; Hewer A; Phillips DH; Ryberg D; Haugen A; Harris CC
    Cancer Res; 2001 Sep; 61(17):6350-5. PubMed ID: 11522624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers.
    Yoon JH; Smith LE; Feng Z; Tang M; Lee CS; Pfeifer GP
    Cancer Res; 2001 Oct; 61(19):7110-7. PubMed ID: 11585742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
    Olivier M; Hussain SP; Caron de Fromentel C; Hainaut P; Harris CC
    IARC Sci Publ; 2004; (157):247-70. PubMed ID: 15055300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India.
    Katiyar S; Dash BC; Thakur V; Guptan RC; Sarin SK; Das BC
    Cancer; 2000 Apr; 88(7):1565-73. PubMed ID: 10738214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts.
    Denissenko MF; Koudriakova TB; Smith L; O'Connor TR; Riggs AD; Pfeifer GP
    Oncogene; 1998 Dec; 17(23):3007-14. PubMed ID: 9881702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical and physical carcinogenesis: advances and perspectives for the 1990s.
    Harris CC
    Cancer Res; 1991 Sep; 51(18 Suppl):5023s-5044s. PubMed ID: 1884379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
    Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
    Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular epidemiology of human cancer.
    Hussain SP; Harris CC
    Toxicol Lett; 1998 Dec; 102-103():219-25. PubMed ID: 10022257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers.
    Denissenko MF; Pao A; Pfeifer GP; Tang M
    Oncogene; 1998 Mar; 16(10):1241-7. PubMed ID: 9546425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations?
    Pfeifer GP; Denissenko MF
    Environ Mol Mutagen; 1998; 31(3):197-205. PubMed ID: 9585258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens.
    Puisieux A; Lim S; Groopman J; Ozturk M
    Cancer Res; 1991 Nov; 51(22):6185-9. PubMed ID: 1933877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene.
    Cerutti P; Hussain P; Pourzand C; Aguilar F
    Cancer Res; 1994 Apr; 54(7 Suppl):1934s-1938s. PubMed ID: 7907948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan.
    Lunn RM; Zhang YJ; Wang LY; Chen CJ; Lee PH; Lee CS; Tsai WY; Santella RM
    Cancer Res; 1997 Aug; 57(16):3471-7. PubMed ID: 9270015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and K-ras mutations in lung cancers from former and never-smoking women.
    Vähäkangas KH; Bennett WP; Castrén K; Welsh JA; Khan MA; Blömeke B; Alavanja MC; Harris CC
    Cancer Res; 2001 Jun; 61(11):4350-6. PubMed ID: 11389059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particles.
    Andersson M; Jönsson M; Nielsen LL; Vyberg M; Visfeldt J; Storm HH; Wallin H
    Cancer Epidemiol Biomarkers Prev; 1995; 4(7):765-70. PubMed ID: 8672994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.